S/MARter Immunotherapies
Platforms
selecTCR
Tcelltech has developed an AI-guided classifier which identifies tumor-targeting T cell receptors (TCRs) within days (see https://www.nature.com/articles/s41587-024-02161-y), immediately available for cell manufacturing.
A web-based tool @ http://predictcr.com allows for interrogating existing datasets. This platform not only identifies therapeutic T cell receptors but is also developed to detect T cell signatures for predicting and monitoring response to immunotherapies.
Our predicTCR has been validated in melanoma, colorectal, pancreatic, lung and brain cancer.
nanoSMAR
We have developed nanoSMAR, a novel, minimally-sized, episomal DNA vector platform which possesses an unlimited genetic cargo capacity and provides robust and persistent gene expression with minimal disruption to cell homeostasis. It is non-toxic and non-immunogenic.
Tcelltech has successfully demonstrated the efficacy of nanoSMAR in a diverse range of applications, including cell therapy, gene therapy, and regenerative medicine. From these data, nanoSMAR appears to be greatly superior to current viral vector-based strategies.
In 2026, nanoSMAR will undergo clinical validation in a TCR-mediated cell therapy trial.
We are actively looking for licensing partners for our nanoSMAR vector platform.
© 2025 Tcelltech GmbH. All rights reserved.
Wir benötigen Ihre Zustimmung zum Laden der Übersetzungen
Wir nutzen einen Drittanbieter-Service, um den Inhalt der Website zu übersetzen, der möglicherweise Daten über Ihre Aktivitäten sammelt. Bitte überprüfen Sie die Details in der Datenschutzerklärung und akzeptieren Sie den Dienst, um die Übersetzungen zu sehen.